Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01984281
Other study ID # 13804413.3.1001.5133
Secondary ID
Status Completed
Phase N/A
First received November 8, 2013
Last updated February 13, 2017
Start date November 2013
Est. completion date December 2015

Study information

Verified date February 2017
Source Federal University of Juiz de Fora
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a pedometer-based unsupervised exercise program is more effective than a general exercise recommendation to increase lifestyle physical activity in adult patients with asthma.


Description:

The patients will be randomized in two groups: the intervention group will receive a standardized advice to physical activity practice plus pedometers and step goals to achieve over the next twelve weeks and the control group will receive the same standardized advice to physical activity practice and usual care.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Asthma diagnosis for at least 6 months (according to Global Initiative for Asthma criteria)

- Regular drug therapy (inhaled corticosteroids or inhaled corticosteroids plus long-acting beta-agonists)

- Clinical stability during the run-in period (3 weeks)

Exclusion Criteria:

- Physical activity practice over once a week

- Disabling musculoskeletal disease

- Cardiopathy

- Other lung disease

- More than 10 pack-years of smoking

- Pregnancy

- Refusal to participate

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Pedometer-based physical activity prescription
After baseline assessments, both groups will receive a educational session, regarding important aspects of asthma plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes). Only the experimental group will receive a pedometer-based physical activity prescription, consisting of targets (steps per day) to be achieved. The initial target will be determined based on the average of steps per day assessed during the baseline assessments plus 1000 steps. The targets will be biweekly. Both groups will be contact once a week (by phone) and will be asked to return for asthma control assessments once a month.

Locations

Country Name City State
Brazil University Hospital of the Federal University of Juiz de Fora Juiz de Fora Minas Gerais

Sponsors (1)

Lead Sponsor Collaborator
Federal University of Juiz de Fora

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lifestyle physical activity The lifestyle physical activity will be estimated as the mean number of steps taken in six days using a pedometer (SW200, YAMAX,Tokyo, Japan) 12 weeks
Secondary Exercise capacity Exercise capacity will be assessed through the six-minute walking teste. 12 weeks
Secondary Asthma Health related quality of life Asthma Health related quality of life will be assessed through the Asthma Quality of Life Questionnaire. 12 weeks
Secondary Asthma Control Asthma Control will be assessed through the Asthma Control Questionnaire 12 weeks
Secondary Depression and anxiety Depression and anxiety will be assessed through the Hospital Anxiety and Depression Scale 12 weeks
Secondary Asthma exacerbations Asthma exacerbations will be assessed through exacerbation diaries. 12 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device